Evotec SE and Bristol-Myers Squibb have expand their collaboration to include additional cell lines, triggering a $6 million payment from BMS.  Evotec and Celgene, a Bristol-Myers Squibb company, initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases with unmet medical need. This collaboration uses an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s t...